| Date |
Event |
Presentation |
Speakers |
|
December 4, 2012
|
4th World Epigenetics Summit
|
Epigenetics - Impact for Translational and Drug Safety Sciences
|
Remi Terranova
|
|
November 3, 2010
|
DIA’s 8th Annual Canadian Meeting: “Keeping Canada on the Map: Fostering Innovation and Access to Drugs in Canada�
|
TRACK 1 – Clinical Development - Innovations in Clinical Development
|
Diane Colizza
|
|
|
|
TRACKS 2 and 3 – Reimbursement/Regulatory - Common Drug Review Pre-NOC
|
Alain Boisvert
|
|
|
|
Adaptive Clinical Trial Designs: Where Is Industry with Respect to Adaptive Design?
|
Jeffrey Maca
|
|
August 25, 2010
|
Co-Development of Drugs and Diagnostics
|
Lumiracoxib - Seeking a New Path Forward Through Use of a Companion Diagnostic
|
Kevin Carl
|
|
May 19, 2010
|
Towards Personalized Cancer Medicine
|
The Discovery and Application of Cancer Therapeutics in the Genomic Era
|
William R Sellers
|
|
|
|
PANEL DISCUSSION
|
William R Sellers
|
|
November 2, 2009
|
Track 4: Fourth Annual GPCR-based drug discovery
|
Targeting GPCR Activity: Conventional and Novel Label-free cAMP Assays Sandra Siehler, Ph.D., Research Investigator II, Novartis Institute for BioMedical Research
|
Sandra Siehler
|
|
November 2, 2009
|
Track 3: Fourth Annual Ion Channels as Therapeutic Targets
|
Evaluation of Available Technologies for Ligand-gated Ion Channel Safety Profiling and Screening
|
Gul Erdemli
|
|
September 24, 2009
|
Track 2: Implementing Personalized Medicine : Inaugural Targeted Therapy
|
Biomarkers - Driven Drug and Diagnostic Co-Development in Oncology: Current Trends and Future Approaches
|
Miro Venturi
|
|
August 24, 2009
|
Specialized Protein Expression Systems
|
Baculovirus Generated Proteins for Structure-Based Drug Design: Lessons Learned
|
James Groarke
|
|
|
|
Exploring the Myth of Glycosylation for Crystallization
|
Paul Ramage
|
|
August 17, 2009
|
Fourth Annual Novel Vaccines: Design & Development
|
Structure-Based Rational Design of HIV Env Immunogens for Vaccine Development
|
Indresh K. Srivastava
|
|
August 5, 2009
|
Drug Safety Strategies to De-Risk Compounds
|
in silico Methods in Drug Safety
|
Josef Scheiber
|
|
July 1, 2009
|
Advances in Oral Dose Manufacturing
|
Assessing the Effects of API Particle Size
|
Jeewan Thakur
|
|
|
|
Applying Solid Dispersion and Nanoparticulate Manufacturing Technologies for Enhanced Drug Delivery
|
Carsten Timpe
|
|
June 10, 2009
|
Second Annual Hepatotoxicity and Drug Safety
|
KEYNOTE PANEL DISCUSSION
|
Laszlo Urban
|
|
June 9, 2009
|
Inaugural The Expanding Impact of New Animal Models in Drug Safety
|
Early Prediction of Clinical Adverse Drug Reactions: in vitro Safety Pharmacology
|
Laszlo Urban
|
|
June 8, 2009
|
RNAi for Functional Screens
|
Development of a Flexible RNAi Screening Platform for Drug Discovery
|
Anthony Orth
|
|
|
|
Chairperson’s Remarks
|
Anthony Orth
|
|
June 4, 2009
|
Structure-Based Drug Design
|
Main Conference
|
Indresh K. Srivastava
|
|
June 1, 2009
|
Combination Products
|
Best Practices for Performing Risk Assessment: How are small and large companies doing this?
|
Gangadhar Sunkara
|
|
|
|
Chairperson’s Opening Remarks
|
Gangadhar Sunkara
|
|
May 19, 2009
|
Amorphous Materials
|
Evaluation of the Performance of Amorphous Dispersion
|
Dieter Becker,
|
|
May 12, 2009
|
BioAvailability and BioEquivalence
|
Statistical Issues in Biosimilarity
|
Sandro Gsteiger
|
|
April 22, 2009
|
PI 3-Kinase Signaling in Disease (Z3)
|
Keynote Address
|
William R Sellers
|
|
April 7, 2009
|
Kinase Inhibitor Chemistry - Charting the Chemical Space
|
Iterative Kinase Medium-Throughput Screening with 2D profile-QSAR and 3D AutoShim Models
|
Eric Martin
|
|
April 6, 2009
|
Fourth Annual FRAGMENT-BASED DRUG DISCOVERY
|
Virtual Fragment Linking: An Approach to Identify Potent Binders from Low Affi nity Fragment Hits
|
Meir Glick
|
|
March 17, 2009
|
Bio Medical Asia 2009
|
Concept for integration of QbD for enhanced efficiency in biologics process development
|
Christian H. Leist
|
|
March 16, 2009
|
High Throughput Screening for Biological Systems
|
IN VITRO SCREENING FOR METABOLIC STABILITY TO PROVIDE CHEMISTRY ALTERNATIVES
|
Alfred Zimmerlin
|
|
|
|
MODULATION OF mRNA STABILITY AS A DRUG DISCOVERY PLATFORM
|
Christian Parker
|
|
February 24, 2009
|
Pharmaceutical Analysis Course
|
Overview of the regulatory directives governing the commercial area
|
Andreas Trute
|
|
February 23, 2009
|
Advances and Progress in Drug Design VIII
|
KEY ASPECTS FOR THE DESIGN OF A COMPREHENSIVE DRUG DISCOVERY SCREENING COLLECTION
|
Edgar Jacoby
|
|
February 17, 2009
|
Pharma/Biotech Patent Litigation
|
Chair’s Opening Remarks
|
Peter de Weerd
|
|
|
|
Ensuring that Strategic Litigation Decisions are Aligned with International Business Goals
|
Peter de Weerd
|
|
February 9, 2009
|
Immunogenicity for Biologics 2009
|
Parallel analysis of exposure and immunogenicity by Biacore in pre-clinical studies
|
Annette Zaar
|
|
February 8, 2009
|
CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development
|
Session 3: Chemistry in Support of Lead Discovery/Screening, Hit Validation, and Natural Products
|
Jeremy S. Caldwell
|
|
|
|
Session 6: Chemistry in Support of Cancer Drug Discovery/Case Histories II
|
Jean Cuiné,
|
|
January 26, 2009
|
|
Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks
|
J Carl Barrett
|
|
January 26, 2009
|
Biomarker Assay Development
|
Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks
|
J Carl Barrett
|
|
|
|
Opportunities and Challenges of Biomarker Assays in Drug Development
|
Francois Legay
|
|
|
|
Target-Related Pharmacodynamic Analysis to Guide Successful Development of Biological Therapies: Novel Biomarker Concepts and Analytical Strategies
|
Miro Venturi
|
|
January 26, 2009
|
Translational Cancer Medicine
|
Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks
|
J Carl Barrett
|
|
|
|
TRANSLATIONAL IMAGING : Translational Molecular Imaging: Oncology
|
Syed Mahmood
|
|
January 26, 2009
|
7th Annual Partnering with Central Labs
|
B2 : The Use of Imaging Biomarkers in Phase I/II trials
|
Haren Rupani
|
|
|
|
Technical Hot Topics
|
Haren Rupani
|
|
|
|
Track A : Improve Patient Care, Transparency and Process Efficiency in Global Studies
|
Scott Sawicki
|
|
|
|
Track A : Central Lab Cost Drivers and Logistics Discussion Forum
|
Scott Sawicki
|
|
January 5, 2009
|
High Content Analysis
|
High-Content Screen to Look for Inhibitors of Virus Entry
|
Marjo Simonen
|
|
|
|
Evaluation of Data Analysis Tools for the Multivariate Classification of Compound Responses Detected by High-Content Screening
|
Anne Kuemmel
|
|
December 9, 2008
|
3rd Annual Congress Strategies to enhance Solubility and Drug Absorption
|
Drug solubilisation strategies: Applying solid dispersion and nanoparticulate formulation approaches in drug development
|
Carsten Timpe,
|
|
|
|
Lipid-based drug delivery systems to enhance solubility and absorption of poorly water-soluble drugs
|
Jean Cuiné,
|
|
|
|
From animal-to-man: Pharmacokinetics and scalability to humans - a formulators’ perspective
|
Dieter Becker,
|
|
December 2, 2008
|
2nd Annual:Outsourcing Preclinical Development
|
Outsourcing DMPK studies
|
Miro Venturi,
|
|
December 2, 2008
|
2nd Annual: Pre-clinical and clinical safety testing for new drugs
|
Improving translation to clinical trials through the use of human hepatocytes in culture
|
Armin Wolf,
|
|
|
|
What could be introduced into the pre-clinical toolkit to more accurately predict TdP risk. Is this necessary?
|
Bérengère Dumotier
|
|
December 2, 2008
|
4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development
|
1: The use of in vivo models in drug discovery imaging
|
Thomas Krucker,
|
|
|
|
2 : Panel Debate: How translatable is preclinical and clinical imaging?
|
Raymond Josephsson,
|
|
|
|
2 : The importance of translatability in imaging and how this can improve preclinical and clinical trials
|
Raymond Josephsson,
|
|
|
|
2 : Exploratory imaging in oncology clinical trials - Where are we today?
|
Haren Rupani
|
|
December 2, 2008
|
2nd Annual Lead Discovery Summit 2008:-Compound Library Design, Synthesis & Acquisition
|
Type 2 and type 3 kinase targeting compound libraries
|
Doriano Fabbro,
|
|
|
|
Decision criteria in cherry picking compounds from large collections for screening campaigns: What have been the most successful methods?
|
Ansgar Schuffenhauer,
|
|
December 2, 2008
|
The 8th World Drug Discovery & Development Summit 2008
|
PREDICTING DRUG PROMISCUITY
|
Jacques Hamon
|
|
November 26, 2008
|
4th Annual Audits and Inspections for Clinical Trials and Pharmacovigilance
|
Maximising the value of CRO relationships in developing audits together
|
Elisabetta di Martino,
|
|
November 25, 2008
|
6th Annual Stability Testing for Pharmaceuticals
|
Management of OOS and OOT results
|
Joseph Kottathu
|
|
November 17, 2008
|
Mastering Process Chemistry
|
Large-Scale Synthesis of Discodermolide, a Marine Natural Product for the Treatment of Advanced Solid Tumors
|
Frederick Kinder
|
|
November 17, 2008
|
BIO-Europe 2008
|
What Buyers Want: Understanding What Big Pharma Expect to See in Out-Licensing Documents
|
Axel Maibuecher
|
|
November 12, 2008
|
Third Annual Post-Approval Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle
|
Chairperson’s Remarks
|
John Ferguson
|
|
|
|
Plotting a Strategy for the Best Benefit-Risk Ratio
|
John Ferguson
|
|
November 12, 2008
|
11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements
|
Successfully Negotiating Collaborative Research Agreements with Academic Institutions
|
Stephanie Oestreich
|
|
November 11, 2008
|
Stability Testing for Biologics
|
Characterisation of degradation products of antibodies using HPLC and mass spectrometry
|
Hui Zhao
|
|
November 4, 2008
|
Bioanalytical Autumn School
|
Comparability - choosing the correct analytical tools
|
Claudia Magagnoli
|
|
October 20, 2008
|
Protein Expression Europe
|
The Benefits of Fusion Tags for an Improved Protein Production with E. coli and BEVS
|
Lukas Leder
|
|
|
|
Baculovirus and E.coli- Generated Proteins for Structure-Based Drug Design – Lessons Learned
|
James M Groarke
|
|
October 14, 2008
|
Crystal Form Selection and Crystallisation of API
|
Opening remarks from the Chairperson
|
Peter Karpinski
|
|
|
|
Closing remarks from the Chairperson
|
Peter Karpinski
|
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
The TeGenero Story: What Happened at Northwick Park and Lessons Learned
|
Jenny Sims
|
|
September 29, 2008
|
Genomic Biomarkers
|
Biomarker Application in Oncology Clinical Development
|
Michael Shi
|
|
September 17, 2008
|
BACULOVIRUS TECHNOLOGY
|
Multi-Parallel Protein Production: Overcoming the Challenges to Accelerate Structural Based Drug Design
|
Ian Hunt
|
|
June 19, 2008
|
Virtual Discovery Europe
|
Integration of Image-Based Cytological Phenotypes with Computational Ligand-Target Prediction to Identify Mechanisms of Action
|
Andreas Bender
|
|
June 18, 2008
|
Accelerating Anticancer Agent Development and Validation Workshop
|
Harmonization of International Standards for Oncology Products
|
Daniel Lapadula
|
|
|
|
Panel Discussion
|
Daniel Lapadula
|
|
May 18, 2008
|
G Protein-Coupled Receptors: New Insights in Functional Regulation and Clinical Application (E2)
|
Deorphanized GPCRs
|
Deborah Nguyen
|
|
May 4, 2008
|
Impact China IV: Pharmaceutical R&D Global Summit
|
Keynote Address: Chinese SFDA and Global Drug Development - Quality, Science and Speed
|
Paul Dai
|
|
March 31, 2008
|
Pharmaceutical Sales & Marketing Executive Congress: Generating BIG Returns in a Changing Compliance Environment
|
The ‘State of the Industry’ – Challenges & Opportunities in 2008 and Beyond
|
Lori Ryan
|
|
March 31, 2008
|
China 2008 Pharmaceutical R&D Summit
|
Leveraging Traditional Chinese Medical Knowledge for Modern Medicine: Collaborating with the Shanghai Institute of Materia Medica
|
Paul Herrling
|
|
|
|
Global Pharma Exchange Roundtable
|
En Li
|
|
|
|
Track II Clinical Research Development in China – Experiences, Improvements and Changes Chairperson’s Opening Remarks
|
Paul Dai
|
|
March 25, 2008
|
Preclinical Development
|
Mechanistic Cardiac Modeling: Concepts and Utility in Drug Development
|
Anna Georgieva
|
|
|
|
Predictive Value of in Vitro Safety Studies
|
Willi Suter
|
|
|
|
Imaging in Phase II/III Clinical Development
|
Haren Rupani
|
|
March 25, 2008
|
TRANSLATIONAL MEDICINE
|
Imaging in Phase II/III Clinical Development
|
Haren Rupani
|
|
March 25, 2008
|
TRENDS IN DRUG SAFETY
|
Mechanistic Cardiac Modeling: Concepts and Utility in Drug Development
|
Anna Georgieva
|
|
|
|
Predictive Value of in Vitro Safety Studies
|
Willi Suter
|
|
March 19, 2008
|
The Healthcare Dealmaking Symposium
|
Licensing Deals
|
Jeremy M. Levin
|
|
February 19, 2008
|
Screening Europe
|
Track A Modern Approaches for an Old Problem: High-Throughput Screening and Compound Profiling of Proteases
|
Lorenz Mayr
|
|
|
|
Track B Emerging GPCR Assay Technologies for Drug Discovery
|
Sandra Siehler
|
|
February 18, 2008
|
Fragment-based Lead Discovery Conference
|
Successes and Surprises with Fragments
|
Wolfgang Jahnke
|
|
|
|
Morning Session: Methods & Emerging Technologies, Part I
|
Wolfgang Jahnke
|
|
|
|
In vivo Incorporation of NMR-active Unnatural Amino Acids
|
Bernhard Geierstanger
|
|
December 4, 2007
|
7th World Drug Discovery & Development Summit 2007
|
Conference room 2 OPTIMISING TECHNOLOGIES TO INCREASE SPEED TO CLINIC AND SPEED TO MARKET
|
Hans-Peter Knopf
|
|
December 1, 2007
|
47TH American Socieity of Cell Biology
|
Solving Cell Culture Problems:
|
Lori Ryan
|
|
November 15, 2007
|
Second Annual Drug Development India : Planning and Managing Drug Discovery & Development Activities Nov(15-16)
|
CONTRIBUTION OF ACADEMIC INSTITUTES (13:30-15:00)
|
Gangadhar Sunkara
|
|
|
|
CONTRIBUTION OF ACADEMIC INSTITUTES: Pharmaceutical Research and Development Environment in India: The Contribution of Aca-demic Institutes (13:30-14:00)
|
Gangadhar Sunkara
|
|
|
|
PRECLINICAL DEVELOPMENT AND CHALLENGES (15:30-18:45)
|
Gangadhar Sunkara
|
|
|
|
PRECLINICAL DEVELOPMENT AND CHALLENGES: INTERACTIVE PANEL :Partnership and Outsourcing Deals in India – Successes and Failures (17:00-17:45)
|
Gangadhar Sunkara
|
|
November 5, 2007
|
Bio-Pharma Alliance Summit Nov (05-06)
|
The Novartis / Human Genome Sciences Albuferon Alliance – Key Success Factors in Driving Successful Biotech/Big Pharma Alliances (14:35-15:15)
|
Mark Coflin
|
|
October 17, 2007
|
Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18)
|
CRAC – AN EMERGING TARGET (08:35-09:40)
|
Martin Gosling
|
|
|
|
CRAC – AN EMERGING TARGET: Chairperson’s Remarks (08:35-08:40)
|
Martin Gosling
|
|
|
|
TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY: Screening Ion Channel Targets with Therapeutic Potential in Respiratory Disease: Application of Automated Electrophysiology (09:40-12:25)
|
Martin Gosling
|
|
|
|
TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY (09:40-12:25)
|
Martin Gosling
|
|
October 16, 2007
|
Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17
|
SESSION I: LAYING THE GROUND WORK FOR EARLY DECISION MAKING (13:45 - 19:00)
|
Jose Pinheiro
|
|
|
|
SESSION I: Evaluating Adaptive Dose-Ranging Studies: Conclusions and Recommendations from the PhRMA Working Group (16:00 - 16:30)
|
Jose Pinheiro
|
|
October 15, 2007
|
2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16)
|
Keynote Presentation (08:45-09:30)
|
J Carl Barrett
|
|
October 11, 2007
|
Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12)
|
SCREENING AGAINST MULTIPLE TARGETS (Shared Session with Drug Repositioning Summit) (12:30-17:15)
|
Jeremy S. Caldwell, Laszlo Urban
|
|
|
|
SCREENING AGAINST MULTIPLE TARGETS: Integrative In Vitro Safety Pharmacology Profiling to Predict Clinical Adverse Effects (15:45-16:15)
|
Laszlo Urban
|
|
|
|
SCREENING AGAINST MULTIPLE TARGETS: Automated Robotic Molecular Profiling in Cells for New Therapeutic Directions (14:15-14:45)
|
Jeremy S. Caldwell
|
|
|
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30)
|
Andreas Bender
|
|
|
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Compound Profiling by Predicting On-Target Activities, Compound Promiscuity and Adverse Drug Reactions (16:00-16:30)
|
Andreas Bender
|
|
October 10, 2007
|
Drug Repositioning Summit: Finding New routes to success (Oct 10-11)
|
SCREENING AGAINST MULTIPLE TARGETS: Automated Robotic Molecular Profiling in Cells for New Therapeutic Directions (14:15-14:45)
|
Jeremy S. Caldwell
|
|
|
|
SCREENING AGAINST MULTIPLE TARGETS (Shared Session with Compound Profiling) (13:30-17:15)
|
Jeremy S. Caldwell, Laszlo Urban
|
|
|
|
SCREENING AGAINST MULTIPLE TARGETS: Broad-Scale In Vitro Pharmacology Profiling to Predict Clinical Adverse Effects and for ADME Profiling (15:45-16:15)
|
Laszlo Urban
|
|
October 2, 2007
|
IVT 's Lab Week
|
Requirements Definition | Session 8
|
Susan Cleary, Parsa Famili
|
|
|
|
Writing Requirements Keeping Validation in Mind | Session 8
|
Susan Cleary, Parsa Famili
|
|
|
|
Finalizing the System | Session 8
|
Susan Cleary, Parsa Famili
|
|
|
|
Interactive Exercise | Session 8
|
Susan Cleary, Parsa Famili
|
|
September 27, 2007
|
Protein Expression Europe (Sep 27-28)
|
Drug Discovery Applications (13:00-15:15)
|
Lorenz Mayr
|
|
|
|
Drug Discovery Applications: Miniaturization and Automation of Protein Expression for High-Throughput Screening and Structural Biology (13:15-13:45)
|
Lorenz Mayr
|
|
September 19, 2007
|
Baculovirus Technology (Sep 19-20)
|
Protein Production (13:45-16:00)
|
Ian Hunt
|
|
|
|
Protein Production: Baculovirus Mediated Protein Production - Overcoming the Challenges to Accelerate Drug Discovery (13:50-14:25)
|
Ian Hunt
|
|
|
|
Protein Expression: A Fast and Multi-Parallel Approach for Small-Scale Expression Screening Using the BEVS System (16:30-17:00)
|
Aline Tirat-Boeuf
|
|
|
|
Protein Expression (16:00-19:00)
|
Aline Tirat-Boeuf
|
How We Rank